The New York Times – Business:
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
Author: RSS Feed
This post first appeared in The New York Times – Business. Read the original article.